University of California, San Francisco Deal History & Licensing Activity
University of California, San Francisco is a life sciences. Over the past three years, University of California, San Francisco has been involved in 1 licensing and acquisition transaction, with a primary focus on Antibodies (2 deals). The company currently has 50 active clinical trials, primarily in CNS Disorders.
Deals (12mo)
1
Active Trials
50
Top Modality
Antibodies
Focus Area
CNS Disorders
University of California, San Francisco Recent Deal Activity
Licensing, acquisition, and partnership transactions involving University of California, San Francisco in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| NKTR-0165 | Nektar Therapeutics Inc. | Antibodies | Preclinical | collaboration | Feb 2026 |
University of California, San Francisco Pipeline Focus
Therapeutic areas and modalities where University of California, San Francisco is most active based on deal history and clinical trial data.
University of California, San Francisco Strategic Signals
Key indicators of University of California, San Francisco's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
University of California, San Francisco Clinical Pipeline
University of California, San Francisco has 50 active clinical trials across 6 development phases.
21
Not Applicable
7
Phase 4
5
Unknown
7
Phase 1
9
Phase 2
1
Phase 3
See How Your Asset Matches University of California, San Francisco's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for CNS Disorders assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About University of California, San Francisco Licensing & Deal Activity
University of California, San Francisco is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, University of California, San Francisco ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for University of California, San Francisco include CNS Disorders (7 deals and trials), Infectious (7 deals and trials), Solid Tumors (6 deals and trials), and Neurology (2 deals and trials). In terms of modality, University of California, San Francisco has shown particular interest in antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for University of California, San Francisco and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against University of California, San Francisco's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.